Management of atherothrombotic risk factors in high-risk Canadian outpatients

Canadian Journal of Cardiology

Volumn 25, Issue 6, 2009, Pages 345-351

  Bell, Alan ^a,j   Hill, Michael D ^b   Herman, Robert J ^c   Girard, Manon ^d   Cohen, Eric ^e   Goodman, Shaun ^f   Mehta, Pravin ^g   Roussin, Andre ^h   Turpie, Graham ⁱ  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF CALGARY   (Canada)

^c UNIVERSITY OF CALGARY   (Canada)

^d SANOFI   (France)

^e UNIVERSITY OF TORONTO   (Canada)

^f ST MICHAEL'S HOSPITAL   (Canada)

^g Laxmi Centre   (Canada)

^h NOTRE DAME HOSPITAL   (Canada)

ⁱ HAMILTON HEALTH SCIENCES   (Canada)

^j NONE   (Canada)

more..

Author keywords

Atherothrombosis; Cardiovascular risk reduction; Coronary artery disease; Ischemic stroke; Peripheral arterial disease

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTICOAGULANT AGENT; ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIGUANIDE DERIVATIVE; CALCIUM CHANNEL BLOCKING AGENT; CHOLESTEROL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; GLITAZONE DERIVATIVE; GLUCOSE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; NONSTEROID ANTIINFLAMMATORY AGENT; SULFONYLUREA;

AGE; AGED; ANKLE BRACHIAL INDEX; ARTERY DISEASE; ARTICLE; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; BLOOD PRESSURE MEASUREMENT; CANADA; CARDIOVASCULAR RISK; CAROTID ARTERY OBSTRUCTION; CEREBROVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CLINICAL FEATURE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DIASTOLIC BLOOD PRESSURE; DRUG USE; FEMALE; GLUCOSE BLOOD LEVEL; HIGH RISK PATIENT; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; OUTPATIENT CARE; RISK MANAGEMENT; RISK REDUCTION; SMOKING; SYSTOLIC BLOOD PRESSURE; THROMBOSIS; UNITED STATES; VASCULAR DISEASE; CARDIOVASCULAR DISEASE; COMPARATIVE STUDY; MIDDLE AGED; OUTPATIENT; PREVALENCE; REGISTER; RISK FACTOR;

ATHEROSCLEROSIS; CANADA; CARDIOVASCULAR DISEASES; DIABETES COMPLICATIONS; HUMANS; HYPERCHOLESTEROLEMIA; HYPERTENSION; MIDDLE AGED; OBESITY; OUTPATIENTS; PREVALENCE; REGISTRIES; RISK FACTORS; THROMBOSIS; UNITED STATES;

EID: 67649949289     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0828-282X(09)70088-1     Document Type: Article

References (32)

1. Mathers CD, Loncar D. Updated projections of global mortality and burden of disease, 2002-2030: Data sources, methods and results. (Version current at November 2006).
2. Ohman EM, Bhatt DL, Steg PG, et al. The REduction of Atherothrombosis for Continued Health (REACH) Registry: An international, prospective, observational investigation in subjects at risk for atherothrombotic events - study design. Am Heart J 2006;151:786.e1-10.
3. Steg PG, Bhatt DL, Wilson PW, et al. One-year cardiovascular event rates in outpatients with atherothrombosis. JAMA 2007;297:1197-206.
4. Bhatt DL, Steg PG, Ohman EM, et al. International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. JAMA 2006;295:180-9.
5. Statistics Canada. Population by year, by province and territory. (Version current at March 6, 2008).
6. Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and management of the metabolic syndrome: An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005;112:2735-52.
7. Canadian Diabetes Association Clinical Practice Guidelines Expert Committee. Canadian Diabetes Association 2003 Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada. Can J Diabetes 2003;27:S1-S152.
8. NCEP Expert Panel. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002;106:3143-421.
9. Khan NA, McAlister FA, Rabkin SW, et al. The 2006 Canadian Hypertension Education Program recommendations for the management of hypertension: Part II - therapy. Can J Cardiol 2006;22:583-93.
10. McPherson R, Frohlich J, Fodor G, Genest J, Canadian Cardiovascular Society. Canadian Cardiovascular Society position statement - recommendations for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease. Can J Cardiol 2006;22:913-27.
11. Abramson BL, Huckell V, Anand S, et al. Canadian Cardiovascular Society Consensus Conference: Peripheral arterial disease - executive summary. Can J Cardiol 2005;21:997-1006.
12. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R. Age-specific relevance of usual blood pressure to vascular mortality: A meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002;360:1903-13.
13. Weber MA. Managing the patient at risk for a second stroke. J Hypertens Suppl 2005;23:S41-7.
14. Canadian Stroke Network and the Heart and Stroke Foundation of Canada: Canadian Stroke Strategy. Canadian Best Practice Recommendations for Stroke Care, 2006. (Version current at April 9, 2008).
15. Joffies MR, Hamer P, MacLean DR, Ultalien GJ, Fodor G. Distribution of blood pressure and hypertension in Canada and the United States. Am J Hypertens 2001;14:1099-105.
16. Tanuseputro P, Manuel DG, Leung M, Nguyen K, Johansen H. Risk factors for cardiovascular disease in Canada. Can J Cardiol 2003;19:1249-59.
17. Antithrombotic Trialists Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002;324:71-86.
18. Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: Prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005;366:1267-78.
19. Fox KM. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: Randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003;362:782-8.
20. Tran H, Anand SS. Oral antiplatelet therapy in cerebrovascular disease, coronary artery disease, and peripheral arterial disease. JAMA 2004;292:1867-74.
21. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000;342:145-53.
22. Erdine S, Ad O, Zanchetti A, et al. ESH-ESC guidelines for the management of hypertension. Herz 2006;31:331-8.
23. Graham I, Atar D, Borch-Johnsen K, et al. European guidelines on cardiovascular disease prevention in clinical practice: Executive summary. Eur Heart J 2007;28:2375-414.
24. Smith SC Jr, Allen J, Blair SN, et al. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: Endorsed by the National Heart, Lung, and Blood Institute. Circulation 2006;113:2363-72.
25. Peyrot M, Rubin RR, Lauritzen T, et al. Resistance to insulin therapy among patients and providers: Results of the cross-national Diabetes Attitudes, Wishes, and Needs (DAVIN) study. Diabetes Care 2005;28:2673-9.
26. Campbell NR, Hemmelgarn B, Tremblay G; Canadian Hypertension Education Program. 2008 Canadian Hypertension Education Program Recommendations: The Scientific Summary - an Annual Update. (Version current at March 21, 2008).
27. Canadian Cardiovascular Society. Consensus Conference on the Evaluation and Management of Chronic Ischemic Heart Disease. (Version current at April 15, 2008).
28. Li C, Engstrom G, Hedblad B, Berglund G, Janzon L. Blood pressure control and risk of stroke: A population-based prospective cohort study. Stroke 2005;36:725-30.
29. Hackam DG, Leiter LA, Yan AT, et al. Missed opportunities for the secondary prevention of cardiovascular disease in Canada. Can J Cardiol 2007;23:1124-30.
30. Petrella RJ, Merikle E, Jones J. Prevalence and treatment of dyslipidemia in Canadian primary care: A retrospective cohort analysis. Clin Ther 2007;29:742-50.
31. Yan AT, Yan RT Tan M, et al. Contemporary management of dyslipidemia in high-risk patients: Targets still not met. Am J Med 2006;119:676-83.
32. Grundy SM, Cleeman JI, Metz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004;110:227-39.